AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017
Apr 5, 2017
29864_dirs_2017-04-05_ea3b55b3-92c9-4d54-8ca5-0b6b63cdfd4e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-04-03
Reporting Person: Chodakewitz Jeffrey (EVP GMDA, CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-04-03 | Common Stock | M | 2291 | $73.51 | Acquired | 124802 | Direct |
| 2017-04-03 | Common Stock | S | 1491 | $108.50 | Disposed | 123311 | Direct |
| 2017-04-03 | Common Stock | S | 600 | $109.32 | Disposed | 122711 | Direct |
| 2017-04-03 | Common Stock | S | 200 | $110.09 | Disposed | 122511 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-04-03 | Stock Option (Right to Buy) | $73.51 | M | 2291 | Disposed | 2024-01-01 | Common Stock (2291) | Direct |
Footnotes
F1: Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
F2: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3: Open market sales reported on this line occurred at a weighted average price of $108.50 (range $108.07 to $108.84).
F4: Open market sales reported on this line occurred at a weighted average price of $109.32 (range $109.09 to $109.70).
F5: The option vests in 16 quarterly installments from 01/02/2014.